玻璃体内地塞米松植入剂与阿柏西普治疗伴浆液性视网膜脱离的初治糖尿病黄斑水肿的比较
一项随机对照研究纳入62例初治糖尿病黄斑水肿伴浆液性视网膜脱离和高反射灶患者,比较地塞米松(DEX)植入剂与阿柏西普的疗效与安全性。12个月随访显示两组视力与中央视网膜厚度均显著改善,DEX组解剖学结果更优,阿柏西普组功能学结果更优;在人工晶状体眼患者中阿柏西普的功能优势消失,DEX组注射次数少被视为优势。
要点
- 两组12个月视力与中央视网膜厚度均较基线显著改善(P < 0.001)。
- 除第1个月外,DEX组中央视网膜厚度降低显著更多(P < 0.05)。
- 校正基线后12个月视力增益 favoring 阿柏西普组(P < 0.01);DEX组注射次数显著更少(2.6 vs 7.2,P = 0.001)。
核心结论
- DEX植入剂与阿柏西普在伴炎症表型的初治糖尿病黄斑水肿患者中均有效且安全。
- 解剖学结果DEX组更好,功能学结果阿柏西普组更好;在人工晶状体眼中阿柏西普的功能优势消失,DEX组注射次数少被视为优势。
研究设计与样本
- 随机对照研究,纳入98眼(62例)初治糖尿病黄斑水肿伴浆液性视网膜脱离和高反射灶患者,随机接受阿柏西普或DEX植入剂治疗。
- 阿柏西普组加载期为每月2 mg注射3次,DEX组为0.7 mg植入剂,之后按需治疗(pro re nata)。
- 主要结局为12个月随访结束时视力与中央视网膜厚度的平均变化。
主要发现
- DEX组48眼(29例),阿柏西普组50眼(33例)。
- 中央视网膜厚度DEX组从基线615.2 µm降至12个月297.7 µm(P < 0.001),阿柏西普组从576.5 µm降至367.4 µm(P < 0.001)。
- 除第1个月外,DEX组中央视网膜厚度降低显著高于阿柏西普组(P < 0.05,Mann-Whitney U检验)。
- 12个月视力DEX组从46.3增至52.7 ETDRS字母,阿柏西普组从47.5增至56.8 ETDRS字母(P < 0.001,配对样本t检验);校正基线后12个月视力增益 favoring 阿柏西普组(P < 0.01)。
- DEX组25%眼、阿柏西普组42%眼获得≥10 ETDRS字母视力增益(P = 0.058);DEX组注射次数显著更少(2.6 vs 7.2,P = 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant versus aflibercept in patients with treatment-naive diabetic macular edema with inflammatory biomarkers. METHODS: Ninety-eight eyes of 62 treatment-naive patients with diabetic macular edema with serous retinal detachment and hyperreflective foci were enrolled. Each patient was randomized to receive either aflibercept or DEX implant treatment. The treatment protocol included 3 monthly injections of 2 mg of aflibercept as a loading phase in the anti-vascular endothelial growth factor group and 0.7 mg of DEX implant in the DEX group and then pro re nata treatment. Primary outcome measures were mean changes in visual acuity and central retinal thickness at the end of the 12-month follow-up. RESULTS: Forty-eight eyes of 29 patients were received DEX implant, and 50 eyes of 33 patients received the aflibercept injection. Mean central retinal thickness decreased from 615.2 µm at baseline to 297.7 µm at 12 months in the DEX group (P < 0.001) and from 576.5 µm to 367.4 µm in the aflibercept group (P < 0.001). Except for the first month, mean central retinal thickness reduction was significantly higher in the DEX group (P < 0.05, Mann-Whitney U Test). Visual acuity improved significantly at the end of the follow-ups (46.3-52.7 Early Treatment Diabetic Retinopathy Study letters in the DEX group and 47.5-56.8 Early Treatment Diabetic Retinopathy Study letters in the aflibercept group at 12 months, P < 0.001, paired-sample t-test). Adjusting by baseline values, the increase in mean visual acuity during the 12-month follow-ups favored the aflibercept group (P < 0.01), 25% of the DEX-treated eyes and 42% of the aflibercept treated eyes experienced 10 or more Early Treatment Diabetic Retinopathy Study letters visual gain (P: 0.058). The DEX group received significantly fewer (2.6 vs. 7.2) injections (P: 0.001). CONCLUSION: It was observed that the both of DEX implant and aflibercept were effective and safe in treatment-naive diabetic macular edema patients with inflammatory phenotype. Anatomical results were found to be better in the DEX group, and functional results were found to be better in the aflibercept group. In pseudophakic eyes, the functional superiority of aflibercept ceased to exist, and the low number of injections in the DEX implant group was seen as an advantage.
引用
- Ozsaygili C, Duru N. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. Retina. 2020. PMID: 30950970. doi:10.1097/IAE.0000000000002537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。